{Reference Type}: Journal Article
{Title}: Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations.
{Author}: Van den Broeck T;van den Bergh RCN;Briers E;Cornford P;Cumberbatch M;Tilki D;De Santis M;Fanti S;Fossati N;Gillessen S;Grummet JP;Henry AM;Lardas M;Liew M;Mason M;Moris L;Schoots IG;van der Kwast T;van der Poel H;Wiegel T;Willemse PM;Rouvière O;Lam TB;Mottet N;
{Journal}: Eur Urol Focus
{Volume}: 6
{Issue}: 2
{Year}: 03 2020 15
{Factor}: 5.952
{DOI}: 10.1016/j.euf.2019.06.004
{Abstract}: Biochemical recurrence (BCR) after primary treatment of localized prostate cancer does not necessarily lead to clinically apparent progressive disease. To aid in prognostication, the European Association of Urology prostate cancer guidelines panel undertook a systematic review and successfully developed a novel BCR risk stratification system (groups with a low risk or high risk of BCR) based on disease and prostate-specific antigen characteristics. PATIENT SUMMARY: Following treatment to cure prostate cancer, some patients can develop recurrence of disease identified via a prostate-specific antigen blood test (ie, biochemical recurrence, or BCR). However, not every man who experiences BCR develops progressive disease (symptoms or evidence of disease progression on imaging). We conducted a review of the literature and developed a classification system for predicting which patients might progress to optimize treatment decisions.